Phase 3 Readout

ANAB: Phase 3 Topline: A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlima

Name: Phase 3 Topline: A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlima
Start: 2027-03-30
End: 2027-03-30

March 30, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: March 30, 2027
Company: ANAPTYSBIO, INC (ANAB)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlima

March 30, 2027

ANAB overview →

Company: ANAPTYSBIO, INC (ANAB)
Indication: Lung Cancer, Non-Small Cell